Occipital Nerve Stimulation for the Treatment of Chronic Migraine Headache.
- Conditions
- Chronic Migraine Headache
- Interventions
- Device: Occipital Nerve Stimulation
- Registration Number
- NCT00200109
- Lead Sponsor
- MedtronicNeuro
- Brief Summary
Background: Medically intractable chronic migraine (CM) is a disabling illness characterized by headache greater than 15 days per month.
Method: A multicenter, randomized, blinded, controlled feasibility study was conducted to obtain preliminary safety and efficacy data on occipital nerve stimulation (ONS) in CM. Eligible subjects received an occipital nerve block, and responsers were randomized to adjustable stimulation (AS), preset stimulation (PS) or medical management (MM) groups.
- Detailed Description
The therapy under investigation involves a Medtronic neurostimulation device which delivers electrical impulses via insulated lead wires placed under the skin near the occipital nerves at the base of the head.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 110
- Diagnosis of Chronic Migraine Headache by International Headache Society (IHS) criteria
- compliance with daily questionnaire
- headache that has not responded to at least two classes of headache medications
- stable headache medication regimen
- previous surgical procedures to disrupt the nerves of the neck relating to the headache
- subjects who may require MRI or Diathermy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Group 2 Occipital Nerve Stimulation See protocol Group 3 Occipital Nerve Stimulation See protocol Group 1 Occipital Nerve Stimulation See protocol Group 4 Occipital Nerve Stimulation See protocol
- Primary Outcome Measures
Name Time Method A primary endpoint is not identified for this feasibility study. No primary endpoint
- Secondary Outcome Measures
Name Time Method Secondary endpoints included: patient daily questionnaire, Migraine Disability Assessment (MIDAS), functional disability, SF-36, acute medication use and subject satisfaction surveys. No secondary endpoint
Trial Locations
- Locations (2)
Contact Medtronic for Exact Location
π¬π§London, United Kingdom
Contact Medtronic for Exact Locations
πΊπΈPhiladelphia, Pennsylvania, United States